STOCK TITAN

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
BiomX appoints Susan Blum to its Board of Directors, bringing extensive finance and accounting experience to guide the company's growth. Ms. Blum, currently the CFO of Melinta Therapeutics, , will chair the audit committee, aiding BiomX in integrating Adaptive Phage Therapeutics and advancing clinical programs.
BiomX nomina Susan Blum nel suo Consiglio di Amministrazione, apportando un'ampia esperienza finanziaria e contabile per guidare la crescita dell'azienda. La signora Blum, attualmente CFO di Melinta Therapeutics, presiederà il comitato di revisione, assistendo BiomX nell'integrazione di Adaptive Phage Therapeutics e nel progredire i programmi clinici.
BiomX nombra a Susan Blum para su Junta Directiva, aportando una amplia experiencia en finanzas y contabilidad para guiar el crecimiento de la compañía. La Sra. Blum, actualmente la CFO de Melinta Therapeutics, presidirá el comité de auditoría, ayudando a BiomX en la integración de Adaptive Phage Therapeutics y en el avance de los programas clínicos.
BiomX는 회사 성장을 지도할 풍부한 재무 및 회계 경험을 가진 Susan Blum을 이사회에 임명하였습니다. 현재 Melinta Therapeutics의 CFO인 블럼 여사는 감사 위원회의 의장을 맡아 Adaptive Phage Therapeutics의 통합과 임상 프로그램의 발전을 BiomX에 도움을 줄 것입니다.
BiomX nomme Susan Blum à son conseil d'administration, apportant une vaste expérience en finance et comptabilité pour guider la croissance de l'entreprise. Mme Blum, actuellement directrice financière de Melinta Therapeutics, présidera le comité d'audit, aidant BiomX à intégrer Adaptive Phage Therapeutics et à faire avancer les programmes cliniques.
BiomX beruft Susan Blum in seinen Vorstand und bringt umfangreiche Erfahrungen in Finanzen und Buchhaltung ein, um das Wachstum des Unternehmens zu leiten. Frau Blum, derzeit CFO bei Melinta Therapeutics, wird den Prüfungsausschuss leiten und BiomX bei der Integration von Adaptive Phage Therapeutics und der Weiterentwicklung der klinischen Programme unterstützen.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board.

“We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company’s history,” said Jonathan Solomon, Chief Executive Officer of BiomX Inc. “For nearly two decades, Susan has held executive positions in both finance and accounting within the life sciences sector, and her extensive leadership in these critical areas will provide our company with significant expertise to help guide our continued integration of the recently acquired Adaptive Phage Therapeutics and efficiently optimize our resources to further advance our two clinical-stage programs, BX004 and BX211.”

Ms. Blum is the Chief Financial Officer of Melinta Therapeutics, LLC. (“Melinta”), a company focused on the development and commercialization of innovative therapies for acute and life-threatening illnesses. She joined Melinta in 2016 as the company’s Controller, and then served as Vice President of Finance & Chief Accounting Officer prior to being appointed to the CFO position in 2021. Prior to joining Melinta, Ms. Blum served as Corporate Controller at Textura Corporation from 2013 to 2016, supporting the company’s IPO and transformation into a publicly-traded organization. Ms. Blum also served in leadership roles at Orbitz Worldwide, Inc. (NYSE: OWW) from 2011 to 2013 and at Facet Biotech Corporation and PDL BioPharma, Inc. (Nasdaq: PDLI) from 2004 to 2010, where she was responsible for such functions as external reporting and related compliance, technical accounting and internal controls over financial reporting. Ms. Blum began her career in public accounting at Ernst & Young, where she spent nearly seven years working with a diverse client base ranging from large, public international engagements to development-stage enterprises. Ms. Blum is a Certified Public Accountant, currently serves as a member of the BioNJ Cybersecurity Committee and holds a B.S. in Business Commerce from Santa Clara University.

About BiomX
BiomX is a clinical-stage company developing both natural and engineered phage cocktails and personalized phage treatments designed to target and destroy bacteria in the treatment of chronic diseases. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.

BiomX Contacts

Investor Relations:
LifeSci Advisors, LLC
John Fraunces
Managing Director
(917) 355-2395
jfraunces@lifesciadvisors.com, or

Brian Mullen
LifeSci Advisors, LLC
(203) 461-1175
Bmullen@lifesciadvisors.com

BiomX, Inc.
Anat Primovich
Corporate Project Manager
+972 (50) 697-7228
anatp@biomx.com
Source: BiomX Inc.


FAQ

Who was appointed to BiomX's Board of Directors?

Susan Blum was appointed to BiomX's Board of Directors.

What role will Susan Blum serve on the Board?

Susan Blum will serve as a member and chair of the audit committee of the Board.

What is Susan Blum's current position?

Susan Blum is the Chief Financial Officer of Melinta Therapeutics,

What experience does Susan Blum bring to BiomX?

Susan Blum has held executive positions in finance and accounting within the life sciences sector for nearly two decades.

What are the two clinical-stage programs BiomX is advancing?

BiomX is advancing the BX004 and BX211 clinical-stage programs.

Where did Susan Blum start her career?

Susan Blum started her career in public accounting at Ernst & Young.

What is Susan Blum's educational background?

Susan Blum holds a B.S. in Business Commerce from Santa Clara University.

BiomX Inc.

NYSE:PHGE

PHGE Rankings

PHGE Latest News

PHGE Stock Data

9.88M
13.62M
11.68%
52.31%
0.13%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NESS ZIONA